DEXYCU (Dexamethasone Intraocular Suspension) 9% Retrospective Study 001 (DEXYCURetro)

EyePoint Pharmaceuticals

Status: Completed

Conditions: Cataract

Treatments: Drug: DEXYCU (dexamethasone intraocular suspension) 9%.

Study type: Observational

Funder types: Industry

Identifiers

NCT04290676

DEXYCU Retrospective Study 001

Details and patient eligibility

About

Retrospective study to provide clinical outcomes with DEXYCU (dexamethasone intraocular suspension) 9%.

Full description

This retrospective study is intended to provide large-scale, real-world data on clinical outcomes with DEXYCU (dexamethasone intraocular suspension) 9%.

Enrollment: 527 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

• Male and Female subjects at least 18 years of age
• Subjects who underwent cataract surgery from 12Mar2019 to 15Dec2019 and received DEXYCU

Exclusion Criteria

• Subjects who underwent cataract surgery and did not receive DEXYCU

Trial design

527 participants in 1 patient group

DEXYCU (dexamethasone intraocular suspension) 9%.

Description:

DEXYCU (dexamethasone intraocular suspension) 9%. Single dose, intraocularly in the posterior chamber at the end of surgery. The dose is 0.005 mL of dexamethasone 9% (equivalent to 517 micrograms).

Treatment:

Drug: DEXYCU (dexamethasone intraocular suspension) 9%.